Literature DB >> 23318455

Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.

S Ammoun1, L Provenzano1, L Zhou1, M Barczyk1, K Evans1, D A Hilton2, S Hafizi3, C O Hanemann1.   

Abstract

TAM family receptor tyrosine kinases comprising Tyro3 (Sky), Axl, and Mer are overexpressed in some cancers, correlate with multidrug resistance and contribute to tumourigenesis by regulating invasion, angiogenesis, cell survival and tumour growth. Mutations in the gene coding for a tumour suppressor merlin cause development of multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas occurring spontaneously or as part of a hereditary disease neurofibromatosis type 2. The benign character of merlin-deficient tumours makes them less responsive to chemotherapy. We previously showed that, amongst other growth factor receptors, TAM family receptors (Tyro3, Axl and Mer) are significantly overexpressed in schwannoma tissues. As Axl is negatively regulated by merlin and positively regulated by E3 ubiquitin ligase CRL4DCAF1, previously shown to be a key regulator in schwannoma growth we hypothesized that Axl is a good target to study in merlin-deficient tumours. Moreover, Axl positively regulates the oncogene Yes-associated protein, which is known to be under merlin regulation in schwannoma and is involved in increased proliferation of merlin-deficient meningioma and mesothelioma. Here, we demonstrated strong overexpression and activation of Axl receptor as well as its ligand Gas6 in human schwannoma primary cells compared to normal Schwann cells. We show that Gas6 is mitogenic and increases schwannoma cell-matrix adhesion and survival acting via Axl in schwannoma cells. Stimulation of the Gas6/Axl signalling pathway recruits Src, focal adhesion kinase (FAK) and NFκB. We showed that NFκB mediates Gas6/Axl-mediated overexpression of survivin, cyclin D1 and FAK, leading to enhanced survival, cell-matrix adhesion and proliferation of schwannoma. We conclude that Axl/FAK/Src/NFκB pathway is relevant in merlin-deficient tumours and is a potential therapeutic target for schwannoma and other merlin-deficient tumours.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318455     DOI: 10.1038/onc.2012.587

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.

Authors:  Bridget Shafit-Zagardo; Ross C Gruber; Juwen C DuBois
Journal:  Pharmacol Ther       Date:  2018-03-04       Impact factor: 12.310

2.  Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.

Authors:  Janet L Oblinger; Sarah S Burns; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Exp Neurol       Date:  2017-06-10       Impact factor: 5.330

Review 3.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

4.  CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Authors:  Brigitte C Widemann; Maria T Acosta; Sylvia Ammoun; Allan J Belzberg; Andre Bernards; Jaishri Blakeley; Antony Bretscher; Karen Cichowski; D Wade Clapp; Eva Dombi; Gareth D Evans; Rosalie Ferner; Cristina Fernandez-Valle; Michael J Fisher; Marco Giovannini; David H Gutmann; C Oliver Hanemann; Robert Hennigan; Susan Huson; David Ingram; Joe Kissil; Bruce R Korf; Eric Legius; Roger J Packer; Andrea I McClatchey; Frank McCormick; Kathryn North; Minja Pehrsson; Scott R Plotkin; Vijaya Ramesh; Nancy Ratner; Susann Schirmer; Larry Sherman; Elizabeth Schorry; David Stevenson; Douglas R Stewart; Nicole Ullrich; Annette C Bakker; Helen Morrison
Journal:  Am J Med Genet A       Date:  2014-01-17       Impact factor: 2.802

5.  Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Authors:  Sonam Dilwali; Martijn C Briët; Shyan-Yuan Kao; Takeshi Fujita; Lukas D Landegger; Michael P Platt; Konstantina M Stankovic
Journal:  Mol Oncol       Date:  2015-03-31       Impact factor: 6.603

6.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 7.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

8.  Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas.

Authors:  Alizée Boin; Anne Couvelard; Christophe Couderc; Isabel Brito; Dan Filipescu; Michel Kalamarides; Pierre Bedossa; Leanne De Koning; Carine Danelsky; Thierry Dubois; Philippe Hupé; Daniel Louvard; Dominique Lallemand
Journal:  Neuro Oncol       Date:  2014-02-20       Impact factor: 12.300

Review 9.  New insights into FAK function and regulation during spermatogenesis.

Authors:  N Ece Gungor-Ordueri; Dolores D Mruk; Hin-ting Wan; Elissa W P Wong; Ciler Celik-Ozenci; Pearl P Y Lie; C Yan Cheng
Journal:  Histol Histopathol       Date:  2014-02-27       Impact factor: 2.303

10.  The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Lu Zhou; David A Hilton; Magdalena Barczyk; Clemens Oliver Hanemann
Journal:  Mol Oncol       Date:  2014-08-27       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.